|
|
Product Pipeline
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
Our balanced research and development portfolio is divided into three categories: life cycle management, market development and new product development. - Lifecycle management ensures continuous product improvement by maintaining and increasing competitiveness within our existing product range.
- Market development brings therapies to new markets and new indications by maximizing market opportunities for our existing product range.
- New product development creates specialty therapies to treat life-threatening diseases. It ensures long-term growth primarily through projects aligned with our current marketing channels.
For a brief description of any of the products listed in our pipeline please visit the Product Pipeline Description page.
Core
Capabilities | | | | Research /
Pre-Clinical | Clinical
Development | Registration/
Post-Launch | Life Cycle
Management | | | | Privigen® 10% IVIG | | Zemaira® US | | Gardasil® |
| Market
Development | | Hizentra® 20%
SCIG EU | | Zemaira® EU | | Biostate® EU | PCC New
Indications | Fibrinogen
Concentrate
New Indications |
| | Berinert® | Hizentra® 20%
SCIG US | Riastap®
Congenital
Deficiency US | | Influenza |
| New
Product Development | Novel
Plasma Proteins | Recombinant
Coagulation
Factors | | rVIIa - FP | | rIX - FP | | Vaccines - MERCK | | Vaccines - WYETH | | Vaccines - Solvay | | CSL112 rHDL | | IL-13R | | Discovery Projects | | G-CSF | | CSL362 - AML | P.Gingivalis/POD
CRC-OHS/Sanofi |
| CSL412
Improved Flu | | Vaccines - MERCK | Partnered Vaccine
Programs | | CAM3001 GM-CSFR MedImmune/AZ |
| | H5N1 Pandemic Flu | | H1N1 Pandemic Flu |
|
For a brief description of any of the products listed in our pipeline please visit the Product Pipeline Description page.
|